A direct thrombin inhibitor suppresses protein C activation and factor Va degradation in human plasma: Possible mechanisms of paradoxical enhancement of thrombin generation

Thrombosis Research

Volumn 141, Issue , 2016, Pages 77-83

  Kamisato, Chikako ^a   Furugohri, Taketoshi ^a   Morishima, Yoshiyuki ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Factor Va; Factor Xa inhibitor; Protein C; Thrombin generation; Thrombin inhibitor

Indexed keywords

ACTIVATED PROTEIN C; ACTIVE SITE BLOCKED THROMBIN IIAI; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 5A 307-506; DABIGATRAN; EDOXABAN; MELAGATRAN; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEIN C; THROMBIN; THROMBIN INHIBITOR; THROMBOMODULIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; ANTITHROMBIN; AZETIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE;

ABSORPTION LAG TIME; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; NEGATIVE FEEDBACK; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; THROMBIN TIME; UPREGULATION; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; BLOOD CLOTTING TEST; DRUG EFFECTS; METABOLISM;

ANTITHROMBINS; AZETIDINES; BENZYLAMINES; BLOOD COAGULATION; BLOOD COAGULATION TESTS; ENZYME ACTIVATION; FACTOR VA; HUMANS; PROTEIN C; PROTEOLYSIS; THROMBIN;

EID: 84960468893     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2016.03.005     Document Type: Article

References (25)

1. T. Furugohri, Y. Shiozaki, S. Muramatsu, Y. Honda, C. Matsumoto, K. Isobe, and N. Sugiyama Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models Eur. J. Pharmacol. 514 2005 35 42
2. T. Furugohri, N. Sugiyama, Y. Morishima, and T. Shibano Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system Thromb. Haemost. 106 2011 1076 1083
3. T. Furugohri, T. Fukuda, N. Tsuji, A. Kita, Y. Morishima, and T. Shibano Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats Eur. J. Pharmacol. 686 2012 74 80
4. T. Furugohri, and Y. Morishima Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin Thromb. Res. 136 2015 658 662
5. E. Perzborn, S. Heitmeier, U. Buetehorn, and V. Laux Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo J. Thromb. Haemost. 12 2014 1054 1065
6. B. Dahlback, and B.O. Villoutreix Molecular recognition in the protein C anticoagulant pathway J. Thromb. Haemost. 1 2003 1525 1534
7. C.T. Esmon The protein C pathway Chest 124 2003 26S 32S
8. F.A. Spencer, and R.C. Becker The prothrombinase complex: Assembly and function J. Thromb. Thrombolysis 4 1997 357 364
9. E.W. Davie, K. Fujikawa, and W. Kisiel The coagulation cascade: Initiation, maintenance, and regulation Biochemistry 30 1991 10363 10370
10. K.G. Mann, and M. Kalafatis Factor V: A combination of Dr Jekyll and Mr Hyde Blood 101 2003 20 30
11. G.A. Nicolaes, and B. Dahlback Factor V and thrombotic disease: Description of a janus-faced protein Arterioscler. Thromb. Vasc. Biol. 22 2002 530 538
12. H. Dorani, K.M. Schützer, T.C. Sarich, U. Wall, U. Logren, L. Ohlsson, and U.G. Eriksson Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers Eur. J. Clin. Pharmacol. 63 2007 571 581
13. J. Stangier, B.I. Eriksson, O.E. Dahl, L. Ahnfelt, G. Nehmiz, H. Stähle, K. Rathgen, and R. Svärd Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement J. Clin. Pharmacol. 45 2005 555 563
14. K. Ogata, J. Mendell-Harary, M. Tachibana, H. Masumoto, T. Oguma, M. Kojima, and S. Kunitada Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers J. Clin. Pharmacol. 50 2010 743 753
15. K. Strandberg, M. Kjellberg, R. Knebel, H. Lilja, and J. Stenflo A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma: Use of a catcher antibody specific for the complexed/cleaved form of the inhibitor Thromb. Haemost. 86 2001 604 610
16. T. Suzuki, Y. Yano, M. Sakamoto, M. Uemura, T. Yasuma, Y. Onishi, R. Sasaki, K. Matsumoto, T. Hayashi, N. Maruyama-Furuta, H. Akatsuka, E.C. Gabazza, Y. Sumida, and Y. Takei Correlation of circulating dehydroepiandrosterone with activated protein C generation and carotid intima-media thickness in male patients with type 2 diabetes Diabet. Med. 29 2012 e41 e46
17. S. Tran, and B. Dahlbäck Novel APC-cleavage sites in FVa provide insights into mechanisms of action of APC and its cofactor protein S J. Thromb. Haemost. 8 2010 129 136
18. R.A. Marlar, D.C. Kressin, and R.M. Madden Contribution of plasma proteinase inhibitors to the regulation of activated protein C in plasma Thromb. Haemost. 69 1993 16 20
19. R. Linder, M. Blombäck, N. Egberg, and L. Grip Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C Thromb. Res. 95 1999 117 125
20. C. Mattsson, A. Menschik-Lundin, S. Nylander, E. Gyzander, and J. Deinum Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro Thromb. Res. 104 2001 475 486
21. R. Linder, S. Frebelius, K. Jansson, and J. Swedenborg Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors Blood Coagul. Fibrinolysis 14 2003 139 146
22. T. Furugohri, K. Isobe, Y. Honda, C. Kamisato-Matsumoto, N. Sugiyama, T. Nagahara, Y. Morishima, and T. Shibano DU-176b, a potent and orally active factor Xa inhibitor: In vitro and in vivo pharmacological profiles J. Thromb. Haemost. 6 2008 1542 1549
23. Food and Drug Administration Exanta (Ximelagatran). Integrated Executive Summary of FDA Review for NDA 2004 21 686
24. J. Douxfils, F. Buckinx, F. Mullier, V. Minet, V. Rabenda, J.Y. Reginster, P. Hainaut, O. Bruyère, and J.M. Dogné Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: A systematic review and meta-analysis of randomized controlled trials J. Am. Heart. Assoc. 3 2014 e000515
25. J.W. Eikelboom, S.J. Connolly, M. Brueckmann, C.B. Granger, A.P. Kappetein, M.J. Mack, J. Blatchford, K. Devenny, J. Friedman, K. Guiver, R. Harper, Y. Khder, M.T. Lobmeyer, H. Maas, J.U. Voigt, M.L. Simoons, F. Van de Werf, and R.E.-A.L.I.G.N. Investigators Dabigatran versus warfarin in patients with mechanical heart valves N. Engl. J. Med. 369 2013 1206 1214